FY2024 EPS Estimates for Moderna, Inc. (NASDAQ:MRNA) Reduced by Zacks Research

Moderna, Inc. (NASDAQ:MRNA) – Investment analysts at Zacks Research reduced their FY2024 earnings per share estimates for shares of Moderna in a report released on Wednesday, September 11th. Zacks Research analyst S. Ganoria now expects that the company will post earnings per share of ($9.53) for the year, down from their prior estimate of ($9.38). The consensus estimate for Moderna’s current full-year earnings is ($9.52) per share. Zacks Research also issued estimates for Moderna’s Q4 2024 earnings at ($1.30) EPS, Q2 2025 earnings at ($3.39) EPS, Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($8.74) EPS, Q1 2026 earnings at ($3.11) EPS, Q2 2026 earnings at ($3.10) EPS and FY2026 earnings at ($6.06) EPS.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.62) earnings per share.

MRNA has been the subject of several other research reports. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday. JPMorgan Chase & Co. lowered shares of Moderna from a “neutral” rating to an “underweight” rating and decreased their price target for the company from $88.00 to $70.00 in a report on Friday. Piper Sandler cut their target price on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price for the company in a research report on Wednesday, August 28th. Finally, Evercore ISI reaffirmed an “in-line” rating and issued a $120.00 price target on shares of Moderna in a report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $108.53.

Moderna Trading Down 2.0 %

MRNA stock opened at $68.28 on Friday. The stock has a market cap of $26.17 billion, a price-to-earnings ratio of -4.36 and a beta of 1.67. The business’s 50-day moving average is $95.06 and its 200 day moving average is $111.79. Moderna has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Institutional Investors Weigh In On Moderna

A number of large investors have recently modified their holdings of the business. Ashton Thomas Private Wealth LLC purchased a new position in shares of Moderna in the 2nd quarter worth approximately $26,000. Ogorek Anthony Joseph NY ADV bought a new position in Moderna in the fourth quarter worth about $27,000. Family Firm Inc. bought a new position in shares of Moderna during the second quarter valued at approximately $33,000. Cedar Wealth Management LLC increased its position in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Finally, Westside Investment Management Inc. purchased a new stake in Moderna in the first quarter worth approximately $32,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In related news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the sale, the president now directly owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the completion of the sale, the president now directly owns 1,457,089 shares in the company, valued at approximately $201,311,416.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The disclosure for this sale can be found here. Insiders sold 108,158 shares of company stock worth $13,239,712 in the last 90 days. 15.70% of the stock is owned by company insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.